Shaping the Future
of Biopharma
Partner with life science experts to drive innovation through integrated strategy, purpose-built technology and AI-powered solutions.
Servicing the Biopharmaceutical Sector
9.5/10
Average Satisfaction
Consistently high client ratings highlight our commitment to excellence
150+
Successful Projects
Delivering success across biotech, pharma, and medical devices since 2019
90%
Retention Rate
Highest in industry; trusted by returning clients for proven results
20+
Life Science Expertise
Every team member holds a life science degree (MD, PhD, Msc)
Our mission is to ensure patients get the right treatment faster, powered by evidence, strategy, and digital solutions.
Integrated Strategy Consulting
Enabling smarter strategic decision-making for life sciences organizations
Strategy & Insight
Turning complex market dynamics into clear priorities that accelerate growth, differentiation, and impact.
AI & Digital Transformation
Guiding life sciences leaders through enterprise-wide digital change, from data architecture to AI-enabled operations, to deliver better outcomes faster.
Real-World Evidence
Providing the data strategy, study execution, analytics, and storytelling needed to translate routine-care data into actionable insights across the product lifecycle.
Value, Access, & Outcomes
Developing global value dossiers, pricing strategies, and HEOR studies that support reimbursement, demonstrate value, and secure access across markets.
Medical Strategy & Communications
From insight gathering to scientific storytelling, we support medical teams with strategy, content, and tools that drive credible, evidence-based engagement.
Executive Communications
Transforming complex data and strategy into compelling presentations that resonate with investors, boards, and internal decision-makers.
Industry Gold Standard in IEGPs
At Princeton Biopartners, we set the industry gold standard for Integrated Evidence Generation Planning (IEGP).
Evidence Gap Audits
We begin with precision. Using the Princeton Evidence Architecture™, our proprietary framework powered by more than 300 million U.S. claims, EU5 real-world data, and linked EMR, we audit the evidence base against the full landscape of decision-makers: regulators, HTAs, payers, clinicians, and patients. The result is a dynamic “gap-to-impact” heat map that highlights where new evidence can unlock the greatest value, whether for label expansion, market access, or medical differentiation.
Study Assessment
Not all studies create equal value. We assess your current and planned evidence portfolio, including clinical trials, HEOR models, and observational research, for strategic fit, stakeholder utility, and return on investment. Through the Princeton Evidence Collective™, our global network of more than 450 KOLs and domain experts, we validate design choices and surface missed opportunities. We also identify how studies can be optimized to address multiple evidence gaps, maximizing their reach and impact. Our process reduces redundant spend, accelerates time to evidence, and ensures every study supports a clear access or commercial goal.
IEGP Monitoring
Execution requires more than project plans; it demands real-time visibility and agile decision-making. That is why we built EVEXA™, our proprietary IEGP monitoring platform. EVEXA tracks performance across twelve critical indicators, including study progress, publication timelines, HTA readiness, and stakeholder-aligned outputs. It also assesses how fully each evidence gap has been addressed, linking activity to strategic outcomes. With dynamic dashboards, predictive risk alerts, and concise executive summaries, EVEXA gives leadership a clear, actionable view of progress, risks, and next steps.
Integrated Evidence Generation Platform
EVEXA™
Purpose-Built for Evidence Generation.
Powered by AI.
Venture Fund
We back early-stage healthcare and life sciences startups with funding and the strategic muscle of a leading advisory firm, helping founders navigate growth, access, and commercialization from day one.
Just 2%
In 2024, only 2% of U.S. venture funding went to startups founded solely by women (Pitchbook, 2025).
We’re women-led—and investing to change the stats.
Less than 25%
Fewer than 1 in 4 U.S. pharma companies have successfully scaled AI beyond the pilot phase (McKinsey & Company, 2025).
We know why—and guide AI-native startups through the friction to real partnerships.
37% CAGR
Healthcare AI is growing at 37% annually and is projected to reach $188B by 2030, fueled by U.S. breakthroughs (The Research Insights, 2025).
We back the startups driving life sciences’ AI transformation.